A Description of Canadian and United States Physician Reimbursement for Thrombolytic Therapy Administration in Acute Ischemic Stroke

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Stroke

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.STR.0000155742.46437.65PMID 15692114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

  2006cited by this paper
• population-based study

  2005cited by this paper
• Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study

  2004cited by this paper
• The effect of race and gender on patterns of rt-PA use within a population.

  2003cited by this paper
• Trends in community knowledge of the warning signs and risk factors for stroke.

  2003cited by this paper
• Cuyahoga County Operation Stroke Speed of Emergency Department Evaluation and Compliance With National Institutes of Neurological Disorders and Stroke Time Targets

  2003cited by this paper
• Improving Delivery of Acute Stroke Therapy: The TLL Temple Foundation Stroke Project

  2002cited by this paper
• Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility

  2001cited by this paper
• Why are stroke patients excluded from TPA therapy?

  2001cited by this paper
• Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers: The Influence of Ethnicity

  2001cited by this paper
• Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility

  2001cited by this paper
• Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey.

  2001cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke

  2000cited by this paper
• Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke.

  2000cited by this paper
• Combined Intravenous and Intra-Arterial Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

  2000cited by this paper
• Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

  1999cited by this paper
• Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.

  1999cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial

  1999cited by this paper
• Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

  1998cited by this paper
• Public perception of stroke warning signs and knowledge of potential risk factors.

  1998cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1996cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1995cited by this paper

• Time cost of a nonclosing intravenous thrombolysis service for acute ischemic stroke.

  2015cites this paper
• Code stroke: a mismatch between number of activation and number of thrombolysis.

  2014cites this paper
• Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review

  2013cites this paper
• The Massachusetts Emergency Medical Service Stroke Quality Improvement Collaborative, 2009–2012

  2013cites this paper
• Preventing Chronic Disease

  2013cites this paper
• Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom.

  2012cites this paper
• Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort

  2012cites this paper
• Barriers to the utilization of thrombolysis for acute ischaemic stroke

  2012cites this paper
• The ABCD and ABCD2 Scores and the Risk of Stroke following a TIA: A Narrative Review

  2011cites this paper
• Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.

  2009cites this paper
• Vascular repair mechanisms : Experimental, physiological and clinical studies.

  2009cites this paper
• PRIMARY STROKE CENTER CERTIFICATION

  2008cites this paper
• How Diagnosis-Related Group 559 Will Change the US Medicare Cost Reimbursement Ratio for Stroke Centers

  2007cites this paper
• Slow progressive acceptance of intravenous thrombolysis for patients with stroke by rural primary care physicians.

  2007cites this paper
• Determining Intravenous rt-PA Eligibility in the Emergency Department

  2007cites this paper
• Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004.

  2007cites this paper
• Reasons why few patients with acute stroke receive tissue plasminogen activator.

  2006cites this paper
• Characteristics of an “Ill-Defined” Diagnosis for Stroke: Opportunities for Improvement

  2006cites this paper
• Acute Stroke Treatment in the Community: Improving Our Performance and Expanding Our Options

  2005cites this paper
• Acute stroke treatment in the community: improving our performance and expanding our options.

  2005cites this paper